Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Medical Affairs Reputations: HIV (EU5) 2018

Product Code:
596201139
Publication Date:
April 2018
Format:
PowerPoint
Price:
$6,365

Close rivalries among European HIV medical affairs teams. Will your team come out on top?

In Europe, two HIV medical affairs teams lead the way in terms of interaction frequency and overall quality of interactions, but there’s room for improvement in other areas. The 150 infectious disease specialists we polled from key European markets (France, Germany, Italy, Spain and the UK) provide insights on several medical affairs teams, and opinions are mixed. Improvement in at least one specific area is needed, but are those targeted improvements enough to put your team ahead of the competition?

Discover all the ways you can improve your medical affairs services in Medical Affairs Reputations: HIV (EU5). Comparing 11 major HIV treatments from Gilead, Janssen Cilag, Merck Sharp & Dohme, BMS and ViiV Healthcare, this report reveals:

  • How infectious disease specialists rate your team overall, and on 12 key medical affairs services.
  • Which medical affairs services are most important.
  • How, and how often infectious disease specialists want to meet with your team.
  • What you can do to improve your medical affairs services.

That’s actionable information you can use to turn your team into one that doctors rely on.

Interested in the US market? Click here to see the US Edition.

Request sample pages

Top Takeaways

  • All to play for at the top, limited options at the bottom. Two teams are neck and neck at the top in terms of overall quality of interactions, a chasing pack of 2-3 brands is close by, but brands at the bottom could struggle to make up ground.
  • Information is the #1 priority. The most important medical affairs services all relate to providing information that doctors can use to make better treatment decisions.
  • Physician interaction rates are high. In the past six months, 4 teams have interacted with more than 80 percent of doctors surveyed, and the least active teams saw no more than 49 percent of them.
  • Doctors want to see teams in-person and not too often. The report reveals how, and how frequently your team should engage.
  • Digital interaction still some way off becoming the norm. For the most part, doctors want personal interactions, not emails or phone calls.

Insight into Medical Affairs Teams for 11 HIV Treatments

  • Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate; Gilead)
  • Descovy (emtricitabine/tenofovir alafenamide; Gilead)
  • Genvoya (cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide; Gilead)
  • Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide; Gilead)
  • Triumeq (abacavir/dolutegravir/lamivudine; ViiV Healthcare)
  • Tivicay (dolutegravir; ViiV Healthcare)
  • Isentress (raltegravir; Merck Sharp & Dohme)
  • Edurant (rilpivirine; Janssen Cilag)
  • Prezista (darunavir; Janssen Cilag)
  • Reyataz (atazanavir; Bristol-Myers Squibb)
  • Rezolsta (darunavir/cobicistat; Janssen Cilag)

An Expert-designed Competitive View of Your Medical Affairs Team

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 11 medical affairs teams—answering important questions like:

What do doctors need?

  • How, and how often are they using your medical affairs team?
  • What services do they consider most important?
  • How often should you contact them? What channels are best?

Does your medical affairs team deliver?

  • How memorable are your team’s interactions with doctors?
  • How do doctors rank your team for performance and satisfaction in 12 key areas?
  • How does your team compare to the competition—in each area, and overall?

What needs improvement?

  • Are you delivering the services that are most important to doctors?
  • Where do you need to improve?
  • How can your team enhance its services?

Based on Interviews with Practicing Doctors

We surveyed 150 infectious disease specialists from the EU5 (France, Italy, Germany, Spain, UK)chosen from the largest community of validated physicians in the world.

All respondents:

  • Have been practicing for between 3 and 35 years
  • See at least 5 patients with HIV in a typical month
  • Devote at least 50% of their time to direct patient care
  • Have interacted with at least one listed product’s medical affairs team in the past 6 months

We conducted the survey between March 5-8, 2018.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

  • FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
  • FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved